-
Clinical Ophthalmology
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting
Original Research
(2797) Total Article Views
Authors: Carneiro AM, Mendonça LS, Falcão MS, Fonseca SL, Brandão EM, Falcão-Reis FM
Published Date July 2012 Volume 2012:6 Pages 1149 - 1157
DOI: http://dx.doi.org/10.2147/OPTH.S33017
Received: | 16 April 2012 |
---|---|
Accepted: | 05 June 2012 |
Published: | 19 July 2012 |
Angela M Carneiro,1,2 Luis S Mendonça,1 Manuel S Falcão,1,2 Sofia L Fonseca,1 Elisete M Brandão,1 Fernando M Falcão-Reis1,2
1Department of Ophthalmology of Hospital de São João, Porto, Portugal; 2Faculty of Medicine of University of Porto, Porto, Portugal
Purpose: We compared the efficacy of intravitreal ranibizumab and bevacizumab for treating neovascular age-related macular degeneration using an on-demand regimen.
Methods: A total of 186 wet age-related macular degeneration eyes of 186 treatment-naïve patients were compared retrospectively (67 eyes treated with ranibizumab with 91 treated with bevacizumab). At baseline, mean age, best corrected visual acuity, and angiographic lesion types were similar in both groups. Best corrected visual acuity and ocular coherence tomography were evaluated.
Results: Sixty eyes treated with ranibizumab and 85 eyes treated with bevacizumab completed a 12-month evaluation. At 12 months, mean best corrected visual acuity increased by +6.65 letters with ranibizumab treatment and by +5.59 with bevacizumab treatment (P = 0.64). Visual acuity improved by ≥15 letters in 15 eyes treated with ranibizumab and in 21 eyes treated with bevacizumab (P = 0.75). An overall reduction in ocular coherence tomography central thickness occurred for all time points. The mean number of injections per eye was 5.97 with ranibizumab and 5.92 with bevacizumab (P = 0.90).
Conclusion: Intravitreal therapies with ranibizumab or bevacizumab have similar visual and anatomical results. These results confirm those of comparison of Age-Related Macular Degeneration Treatment Trials in as-needed cohorts in clinical practice. Randomized long-term clinical trials are necessary to examine the systemic safety of these treatments.
Keywords: AMD, anti-VEGF therapy, bevacizumab, choroidal neovascularization, ranibizumab, wet AMD
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Manuel Falcão
Readers of this article also read:
- Interested in being a peer-reviewer?
Click here to register.
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, University of Texas Health Science Center, San Antonio.
- Insight into 144 patients with ocular vascular events during VEGF antagonist injections
- Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
- Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
- Dexmedetomidine sedation in painful posterior segment surgery